Catalyst Dossier · compiled by CeliA 🧫

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

Biotechnology · market cap $45.1B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Jiangsu Hengrui Pharmaceuticals (JHPCY) is a large-cap Chinese biotechnology company trading at approximately $18/share with a market capitalization of ~$45.1B. The company operates a broad pipeline spanning oncology, cardiovascular, metabolic, anesthesia, and hematology indications, with its lead asset SHR-1209 in Phase 3 for Primary Hypercholesterolemia and multiple other assets at Phase 2/3 stages. Several high-importance catalysts are slated across 2026–2027, including Phase 3 readouts for Rivoceranib (Apatinib) and Vicagrel.

The catalyst path

2026-07-15 (est.)Phase 2 · Tegileridine Fumarate lnjectionimp 7/10
2026-11-15 (est.)Phase 2 · Bupivacaine Liposome Injectionimp 7/10
2026-12-15 (est.)Phase 2 · SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316imp 7/10
2026-12-15 (est.)Phase 2 · SHR-3167 Injectionimp 7/10
2027-06-21 (est.)PDUFA · Sumecigrel Capsuleimp 8/10

Pipeline

Asset	Phase	Indication
Bupivacaine Liposome Injection	Phase 2	Local Analgesia Via Nerve Block
SHR-3167 Injection	Phase 2	Diabetes Mellitus, Type 2
HRS-4508+ Capecitabine	Phase 2	Solid Tumor
HRS-9190	Phase 2	Neuromuscular Blockade
HR19042 Capsules	Phase 2	IgA Nephropathy
SHR-1209	Phase 3	Primary Hypercholesterolemia
FRSW117	Phase 2	Severe Hemophilia A
HRS-4508 tablet	Phase 2	Lung Cancer
Famitinib	Phase 2	Colorectal Cancer
Pyrotinib	Phase 3	HER2-positive Breast Cancer
apatinib	Phase 3	Non-Small-Cell Lung Cancer
SHR-1210	Phase 2	Nasopharyngeal Carcinoma
SHR6390	Phase 3	Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
SHR-A1811 Injection	Phase 2	Recurrent or Metastatic Cervical Cancer
Hetrombopag Olamine	Phase 3	Severe Aplastic Anemia
SHR0302	Phase 3	Rheumatoid Arthritis
Hetrombopag	Phase 3	Chemotherapy-Induced Thrombocytopenia
HS-20093 for Injection	Phase 2	Prostate Cancer
Remimazolam Tosilate	Phase 3	General Anesthesia
Propofol	Phase 3	Anesthesia for Elective Surgery Patients

Price & technical context

3-month

-0.8%

6-month

-3.7%

12-month

—

52-wk range

$15.40–$24.18

vs 50-day MA

+5.1%

vs 200-day MA

-4.7%

Realized vol

44.0%

Max drawdown

-36.3%

Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for JHPCY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.